| Outcome Measures: |
Primary: Changes of glycosilated haemoglobin (HbA1c), At least 12 weeks from baseline (visit 3) | Secondary: Changes in fasting plasma glucose, At each visit|Changes in plasma insulin levels, At each visit|Change of Self-monitoring of Blood Glucose (SMBG), for the total study duration|Mean Amplitude Glucose Excursion (MAGE), for the total study duration|Change in lipid profile, V1 (screening) and V5 (end of treatment)|Body weight - Body Mass Index, V1 (screening), V3 (start of titration), V4 (after 12 weeks of treatment), V5 (end of treatment), V6 (end of follow-up)|Total daily dose of insulins (glargine and glulisine), At each visit (starting from V2 for glargine and from V3 for glulisine)|Health related Quality of Life, V2 (start of titration), V4 (after 12 weeks of treatment), V5 (end of treatment)|Hypoglycemic episodes, for the total study duration
|
